THE GENERAL ASSEMBLY OF PENNSYLVANIA

SENATE BILL

No. 675

Session of 2019

INTRODUCED BY BROOKS, BROWNE, HUTCHINSON, STEFANO AND K. WARD, MAY 28, 2019

REFERRED TO HEALTH AND HUMAN SERVICES, MAY 28, 2019

AN ACT

- 1 Providing for certification of buprenorphine office-based
- 2 prescribers; limiting the use of buprenorphine; and imposing
- powers and duties on the Department of Drug and Alcohol
- 4 Programs.
- 5 The General Assembly of the Commonwealth of Pennsylvania
- 6 hereby enacts as follows:
- 7 Section 1. Short title.
- 8 This act shall be known and may be cited as the Buprenorphine
- 9 Medically Assisted Treatment Act.
- 10 Section 2. Definitions.
- 11 The following words and phrases when used in this act shall
- 12 have the meanings given to them in this section unless the
- 13 context clearly indicates otherwise:
- 14 "Buprenorphine." A material, compound, mixture of
- 15 preparation containing buprenorphine or its salts used as
- 16 medically assisted treatment for opioid addiction.
- 17 "Buprenorphine office-based prescriber." A person that is
- 18 assigned a waiver from the Drug Enforcement Administration,
- 19 including a special identification number, commonly referred to

- 1 as the "X" DEA number, and provides office-based prescribing of
- 2 buprenorphine.
- 3 "Department." The Department of Drug and Alcohol Programs of
- 4 the Commonwealth.
- 5 Section 3. Buprenorphine medically assisted treatment.
- 6 (a) Certification. -- The department shall establish a program
- 7 for certification of buprenorphine office-based prescribers as
- 8 qualified by training and experience to prescribe buprenorphine.
- 9 (b) Fee.--A buprenorphine office-based prescriber shall pay
- 10 a fee to the department in order to receive certification under
- 11 subsection (a). The amount of the fee shall not exceed \$500
- 12 during the first year in which the fee may be imposed and
- 13 thereafter shall not exceed an amount sufficient to reimburse
- 14 the department for the administrative cost to administer and
- 15 enforce this act.
- 16 (c) Prohibition. -- No buprenorphine office-based prescriber
- 17 shall prescribe buprenorphine to a patient unless all of the
- 18 following occur:
- 19 (1) The patient provides evidence demonstrating active
- 20 participation in an addiction treatment program licensed by
- 21 the department.
- 22 (2) The evidence of participation in the addiction
- treatment program is documented in the patient's medical
- 24 record.
- 25 (3) The buprenorphine office-based prescriber is
- certified by the department as provided under subsection (a).
- 27 (d) Violations.--
- 28 (1) The department shall report a violation of this act
- 29 to the appropriate licensure board.
- 30 (2) A person who violates this act and is licensed by a

- 1 licensure board under another act shall be subject to
- 2 discipline by the licensure board under the other act for the
- 3 violation, including license suspension or revocation or an
- 4 appropriate fine or other penalty.
- 5 Section 4. Effective date.
- 6 This act shall take effect in 60 days.